Forget about championing one side or another. The politically charged "generics vs. namebrand drug" debate offers an opportunity to study the impacts of process and ingredient variability on drug manufacturing and on clinical effects in patients. (For material to analyze, click here).
Spatially Offset Raman Spectroscopy (SORS---oh, no, not another analytical acronym) , under development in the U.K. at academic labs and a spinoff, promises to facilitate non-invasive testing in the pharmaceutical industry. For more information, read on.
To some people, Process Analytical Technologies (PAT) and Quality by Design (QbD) might seem like the dullest topics imagineable. But they just might be the salvation of an industry dogged by recalls and adverse reaction reports, lawsuits, 483's and other compliance issues (and that's just on the GMP and non...
We love the progressive thinking that's going on in pharma. That's why I enjoy my job and what makes covering this side of the industry so much more interesting and positive than looking at the financial side and all the marketing scandals.
Our editors are keeping busy at the IFPAC 2008 Show in Baltimore. Check our landing page for daily show coverage including video interviews, articles, and product announcements. IFPAC 2008 Show Coverage
This is pretty old news, but it certainly took me by surprise. Just glanced at the online masthead and the byline of an article from the November 2007 issue of Biopharm International and learned that Dr. Hussain has moved from Sandoz to... Philip Morris International? (OK.
The American Association of Pharmaceutical Scientists (AAPS) has announced its 2007 AAPS Fellows, cited for making "remarkable scholarly and research contributions to the pharmaceutical sciences." They will be recognized at the group's annual meeting this week in San Diego, which Bill Swichtenberg will be attending.
Polymorphism, a condition in which an active ingredient can exist in more than one crystal form (each with a potentially different impact), has long bedeviled drug makers and QA/QC departments. Researchers in the U.K. (at the University of Warwick and AstraZeneca) have discovered a new way of using NMR that...
Big Pharma may be feeling the cost pinch in manufacturing, but generic pharma feels it much, much more. Recently, two experts at Dr. Reddy's Laboratories in India discussed the drive to smaller pharma batches and the need for better line balancing. Note their mention of PAT. For more, read on.